DK0725653T3 - Vaccinepræparater - Google Patents

Vaccinepræparater

Info

Publication number: DK0725653T3
Authority: DK; Denmark
Prior art keywords: double mutant; antigen; substituted; manufacture; amino acid
Prior art date: 1993-10-05

Application number

DK94928455T

Other languages

English (en)

Inventor

Mark Roberts

Original Assignee

Celltech Pharmaceuticals Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-05

Filing date

1994-10-04

Publication date

2004-10-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26303633&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0725653(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-10-05 Priority claimed from GB939320454A external-priority patent/GB9320454D0/en

1993-12-02 Priority claimed from GB939324743A external-priority patent/GB9324743D0/en

1994-10-04 Application filed by Celltech Pharmaceuticals Ltd filed Critical Celltech Pharmaceuticals Ltd

2004-10-11 Application granted granted Critical

2004-10-11 Publication of DK0725653T3 publication Critical patent/DK0725653T3/da

Links

229960005486 vaccine Drugs 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
231100000252 nontoxic Toxicity 0.000 abstract 3
230000003000 nontoxic effect Effects 0.000 abstract 3
108010081690 Pertussis Toxin Proteins 0.000 abstract 2
235000001014 amino acid Nutrition 0.000 abstract 2
150000001413 amino acids Chemical class 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 2
238000004519 manufacturing process Methods 0.000 abstract 2
239000004475 Arginine Substances 0.000 abstract 1
241000588832 Bordetella pertussis Species 0.000 abstract 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 1
239000004471 Glycine Substances 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
239000002671 adjuvant Substances 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 abstract 1
230000001681 protective effect Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK94928455T 1993-10-05 1994-10-04 Vaccinepræparater DK0725653T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB939320454A GB9320454D0 (en)	1993-10-05	1993-10-05	Vaccine compositions
GB939324743A GB9324743D0 (en)	1993-12-02	1993-12-02	Adjuvant compositions

Publications (1)

Publication Number	Publication Date
DK0725653T3 true DK0725653T3 (da)	2004-10-11

Family

ID=26303633

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94928455T DK0725653T3 (da)	1993-10-05	1994-10-04	Vaccinepræparater

Country Status (7)

Country	Link
US (2)	US7169399B2 (da)
EP (1)	EP0725653B2 (da)
AT (1)	ATE275970T1 (da)
AU (1)	AU7788194A (da)
DE (1)	DE69434000T3 (da)
DK (1)	DK0725653T3 (da)
WO (1)	WO1995009649A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9513371D0 (en)	1995-06-30	1995-09-06	Biocine Spa	Immunogenic detoxified mutant toxins
ATE275970T1 (de)	1993-10-05	2004-10-15	Celltech Pharmaceuticals Ltd	Impfstoffzusammensetzungen
GB9326174D0 (en)	1993-12-22	1994-02-23	Biocine Sclavo	Mucosal adjuvant
US20030072774A1 (en) *	1994-06-10	2003-04-17	Diane M. Gajewczyk	Proteinaceous adjuvants
US6818222B1 (en)	1997-03-21	2004-11-16	Chiron Corporation	Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7115730B1 (en)	1999-04-27	2006-10-03	Chiron Srl	Immunogenic detoxified mutant E. coli LT-A-toxin
WO2003072016A2 (en) *	2001-11-19	2003-09-04	Becton, Dickinson And Company	Pharmaceutical compositions in particulate form
EP1790358A1 (en)	2005-11-23	2007-05-30	Université de Reims Champagne-Ardennes	Protein constructs designed for targeting and lysis of cells
AU2011238711B2 (en)	2010-03-30	2015-06-18	Pelican Technology Holdings, Inc.	High level expression of recombinant toxin proteins
IN2014CN04700A (da) *	2011-12-21	2015-09-18	Bionet Asia Co Ltd
US9169304B2 (en)	2012-05-01	2015-10-27	Pfenex Inc.	Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2016011155A1 (en)	2014-07-15	2016-01-21	Kapre Subhash V	Genetically detoxified pertussis that maintains intrinsic adjuvant activity

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8727489D0 (en) *	1987-11-24	1987-12-23	Connaught Lab	Detoxification of pertussis toxin
JP2849632B2 (ja) *	1988-04-08	1999-01-20	社団法人北里研究所	ワクチン製剤
HUT53154A (en)	1988-05-05	1990-09-28	New York Health Res Inst	Process for producing protease-defective gram-positive bacteria and utilizing them as host-organizmus for producing recombinant products
AP8900132A0 (en) *	1988-07-22	1991-01-14	Smithkline Biolog	Bordetella pertussis vaccine
ATE127347T1 (de) *	1989-04-28	1995-09-15	Sclavo Spa	Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
US5601826A (en) *	1989-06-30	1997-02-11	The United States Of America As Represented By The Department Of Health And Human Services	Peptide which produces protective immunity against tetanus
DE69018926T2 (de)	1989-09-04	1995-08-24	Wellcome Found	Vakzine gegen Bordetella.
JPH03135923A (ja) *	1989-10-20	1991-06-10	Chemo Sero Therapeut Res Inst	百日咳毒素ｂオリゴマーの構成サブユニットを含有する経鼻接種ワクチン
IT1248735B (it)	1990-06-21	1995-01-26	Sclavo Spa	Vaccini acellulari contro la pertosse
EP0484621A3 (en)	1990-07-11	1992-08-26	American Cyanamid Company	Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
CA2083553A1 (en)	1991-11-25	1993-05-26	Kuniharu Seki	Immunogen composition
IT1253009B (it)	1991-12-31	1995-07-10	Sclavo Ricerca S R L	Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
ATE275970T1 (de)	1993-10-05	2004-10-15	Celltech Pharmaceuticals Ltd	Impfstoffzusammensetzungen
GB9326174D0 (en)	1993-12-22	1994-02-23	Biocine Sclavo	Mucosal adjuvant
US20030072774A1 (en) *	1994-06-10	2003-04-17	Diane M. Gajewczyk	Proteinaceous adjuvants
US6019982A (en)	1994-08-26	2000-02-01	The Administrators Of The Tulane Educational Fund	Mutant enterotoxin effective as a non-toxic oral adjuvant
MXPA01003228A (es)	1998-09-30	2003-06-24	American Cyanamid Co	Holotoxina de colera mutante como un coadyuvante.

1994
- 1994-10-04 AT AT94928455T patent/ATE275970T1/de not_active IP Right Cessation
- 1994-10-04 AU AU77881/94A patent/AU7788194A/en not_active Abandoned
- 1994-10-04 WO PCT/GB1994/002152 patent/WO1995009649A1/en active IP Right Grant
- 1994-10-04 DE DE69434000T patent/DE69434000T3/de not_active Expired - Fee Related
- 1994-10-04 EP EP94928455A patent/EP0725653B2/en not_active Expired - Lifetime
- 1994-10-04 DK DK94928455T patent/DK0725653T3/da active
2001
- 2001-02-02 US US09/775,909 patent/US7169399B2/en not_active Expired - Fee Related
2007
- 2007-01-09 US US11/651,346 patent/US20100255033A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100255033A1 (en)	2010-10-07
AU7788194A (en)	1995-05-01
ATE275970T1 (de)	2004-10-15
EP0725653A1 (en)	1996-08-14
US7169399B2 (en)	2007-01-30
WO1995009649A1 (en)	1995-04-13
EP0725653B2 (en)	2008-04-02
EP0725653B1 (en)	2004-09-15
DE69434000T2 (de)	2005-01-27
DE69434000T3 (de)	2008-11-06
DE69434000D1 (de)	2004-10-21
US20010018056A1 (en)	2001-08-30

Publication	Publication Date	Title
NZ291262A (en)	1999-02-25	E. coli heat-labile enterotoxin derivatives and their use as oral adjuvants
DK0725653T3 (da)	2004-10-11	Vaccinepræparater
GB9419979D0 (en)	1994-11-16	Vaccine compositions
GB9209118D0 (en)	1992-06-10	Vaccine compositions
NZ323973A (en)	2004-12-24	Vaccine compositions for intranasal administration comprising chitosan and use thereof
NL300188I1 (nl)	2005-06-01	Acellulair vaccin.
HUP9801223A2 (hu)	1998-08-28	Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
DE69317435D1 (de)	1998-04-16	Entzündungshemmende tolerogene und inmonoinhibitorische eigenschaften von karbohyhydrate bindenden peptiden
NZ312502A (en)	1999-03-29	Clostridium difficile toxins as mucosal adjuvants
FR2693655B1 (fr)	1994-10-14	Vaccin antirabique avirulent.
ATE195427T1 (de)	2000-09-15	Pertussistoxin enthaltender influenzaimpfstoff
HK1025220A1 (en)	2000-11-10	Novel saponin compositions and uses thereof
FR2633832B1 (fr)	1991-05-31	Vaccin antirabique avirulent